H.R. 1266: Combating Illicit Xylazine Act

H.R. 1266 would add xylazine to Schedule III of federal drug law. That puts it in the same legal tier as ketamine and anabolic steroids: distributing or possessing it outside approved channels becomes a federal crime, and the supply chain gets tracked.

The hard part isn't the crackdown — it's the carve-out. Xylazine has real veterinary uses, so the bill doesn't ban it. Instead it rewrites the legal definition of who can possess it: a veterinarian, a pharmacy filling a vet's prescription, a pet owner, anyone caring for an animal, plus government animal-control and wildlife programs. Possess it for one of those reasons and the law treats you as a lawful user, not a target — and you don't have to register with the DEA.

The bill also builds in a runway so it doesn't choke off the legitimate supply. Practitioner registration and recordkeeping rules wait 60 days. Labeling, packaging, and distribution rules wait a full year. Companies already making xylazine when the law takes effect are exempt from paying for new facility security upgrades, and the FDA and DEA are told to fast-track their paperwork.

Beyond scheduling, the bill plugs xylazine into ARCOS, the federal system that tracks how controlled drugs move through legal supply chains, so authorities can spot diversion. It directs the U.S. Sentencing Commission to review penalties for xylazine offenses. And it requires the DEA, working with the FDA, to report to Congress within 18 months — and again within four years — on where illicit xylazine is coming from, where it's being diverted, and whether copycat substances are emerging. With 99 cosponsors from both parties, the bill has broader backing than most drug-policy proposals; it still has to clear the Energy and Commerce and Judiciary Committees.